Acute Lung Injury Ventilator Evaluation (ALIVE)
Launched by UNIVERSITY OF WISCONSIN, MADISON · Jul 12, 2013
Trial Information
Current as of August 02, 2025
Terminated
Keywords
ClinConnect Summary
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) represent a spectrum of clinical syndromes of rapid respiratory system deterioration that are associated with both pulmonary and systemic illness. These syndromes are associated with 30-40% mortality with our current standard of care and are responsible for approximately 75,000 deaths in the US yearly. The current evidence-based care consists of a strategy of mechanical ventilation utilizing low lung volumes (ARDSNet ventilation) intended to limit further lung injury from overstretch of the lung induced by the ventil...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age greater than or equal to 18
- • Admitted to intensive care unit
- • Has legally authorized representative (LAR) available to provide informed consent in languages allowed by IRB
- • Has required mechanical ventilator for less than 14 days
- • Meets all of the following American-European Consensus Criteria for Acute Lung Injury or Acute Respiratory Distress Syndrome: a. Acute onset of respiratory compromise, AND b. Bilateral chest radiographic infiltrates, AND c. PaO2/FiO2 ratio less than 300, OR if no arterial blood gas has been drawn by the clinical care team, a saturation O2/FiO2 ratio less than 315 with an O2 saturation less than 97%), AND d. Known pulmonary wedge pressure less than 18 mmHg, OR if pulmonary wedge pressure is not known, left-sided heart failure is not the most likely explanation for the patient's clinical findings of bilateral infiltrates and/or low PaO2/FiO2 ratio
- • Has met ALI criteria for less than 7 days prior to enrollment
- • Approval of intensive care unit attending physician
- • Has arterial catheter in place
- • Meets Clinical Stability Criteria for at least one hour prior to the start of study procedures. Note: Clinical Stability Criteria must be maintained throughout the duration of the intervention period.
- Exclusion Criteria:
- • Patient has a Do Not Resuscitate Order
- • Evidence of increased intracranial pressure (e.g. presence of intraventricular catheter, brain herniation)
- • Patient is pregnant (if pregnancy test was not performed as part of routine clinical care, a urine pregnancy test must be performed for women of childbearing potential after informed consent obtained)
- • Planned transport out of ICU during study protocol
- • Coagulopathy within the past 48 hours (INR greater than 2.0 or PTT greater than 50 seconds)
- • Severe thrombocytopenia within the past 48 hours (platelets less than 20,000 per μL)
- • History of obstructive lung disease (asthma and/or COPD)
- • Patients who are currently prisoners
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Suresh Agarwal, MD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials